Objective-CXCL12 encodes stromal cell-derived factor 1α (SDF-1), which binds to the receptor encoded by CXCR4.
G enome-wide association studies (GWAS) of coronary artery disease (CAD) and myocardial infarction (MI) have identified 10q11.21 as a risk locus. [1] [2] [3] [4] 10q11.21 harbors CXCL12, which encodes stromal cell-derived factor 1α (SDF-1). In addition to the association of CXCL12 with CAD and MI, we reported that the gene coding for its receptor, CXCR4, is associated in GWAS with leukocyte telomere length (LTL). 5 We and others have shown that LTL, in turn, is associated with CAD and MI. 5, 6 The dual GWAS links of the CXCR4-CXCL12 axis with CAD/MI and with LTL makes SDF-1 an attractive protein biomarker for cardiovascular disease (CVD) and related phenotypes.
The CXCR4-CXCL12 axis has been explored in experimental models and in population studies. SDF-1 governs the homing of endothelial progenitor cells from bone marrow to areas of vascular injury for angiogenesis and repair. 7 The Bruneck study reported that plasma SDF-1 levels are inversely related to circulating endothelial progenitor cell numbers. 8 In addition, in the same study, there was an association among CXCL12 genetic variation, circulating SDF-1 levels, and circulating endothelial progenitor cells. 9 CD34+ cell count is an indicator of progenitor cell activity, 10 is associated with CVD, 11 and promotes neovascularization in the context of vascular disease. 12, 13 Thus, alterations in CXCL12 expressionand by inference, increased SDF-1 levels-may affect CD34+ abundance and recruitment in the context of CVD.
Collectively, these findings are consistent with the hypothesis that plasma SDF-1 levels and genetic variations at the CXCL12 and CXCR4 loci are linked to CVD risk and to CVD-related phenotypes through effects on progenitor cell recruitment and LTL dynamics. Thus, we sought to study the association of plasma SDF-1 levels with CVD-related outcomes and to investigate possible mechanistic connections. We hypothesized that higher plasma SDF-1 levels would be associated with increased risk for CVD-related outcomes, with a greater burden of CVD risk factors, and with shorter LTL and lower CD34+ cell numbers. To that end, we examined these relationships in 3359 participants from the Framingham Heart Study.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Baseline Characteristics
The mean age of the study sample was 59 years, and 53% were women. The mean SDF-1 level was 1894 pg/mL (range, 742-17 633 pg/mL). Two individuals with SDF-1 levels >5 SD were excluded from analyses, leaving 3357 with SDF-1 data; 3216 participants had no missing covariates. Baseline clinical characteristics of the 3357 participants with measured SDF-1 levels are summarized in Table 1 .
In unadjusted analyses, higher SDF-1 levels were associated with older age (P<0.0001), waist circumference, higher prevalence of diabetes mellitus, hypertension treatment, and CVD (P<0.0001). In addition, increasing quartiles of SDF-1 were associated with higher levels of low-density lipoproteincholesterol, triglycerides, systolic blood pressure, glucose, and B-type natriuretic peptide (BNP) (P<0.01). In contrast, high-density lipoprotein (HDL)-cholesterol decreased across SDF-1 quartiles (P<0.0001). In multivariable analyses ( Table  I in the online-only Data Supplement), higher SDF-1 levels were associated with older age; lower SDF-1 levels were associated with lower body mass index, HDL-cholesterol, and systolic blood pressure.
SDF-1 and Clinical Outcomes
For analyses of new-onset atherosclerotic CVD, participants with prevalent atherosclerotic CVD (n=168) and missing covariates (n=23) were excluded, and among the 3168 remaining participants, there were 263 incident atherosclerotic CVD events during follow-up (median [ In secondary analyses, we explored the association of SDF-1 with cause-specific mortality (CVD deaths [n=110], cancer deaths [n=199], and deaths from other or unknown causes [n=176]; Table II in the online-only Data Supplement). In risk factor adjusted models, SDF-1 was associated with CVD death (P=0.02) and other or unknown causes of death (P=0.003) but not with cancer death (P=0.22).
SDF-1 Levels and LTL
Of the 1185 individuals who had LTL data, the mean telomere length was 6.9 kbp in men and 7.0 kbp in women. There was no statistically significant association between SDF-1 and LTL (Table 3 ).
SDF-1 and CD34+ Cell Phenotypes
We examined natural log-transformed CD34+ cell numbers (n=1579) in relation to SDF-1 levels. CD34+ frequency was associated with higher SDF-1 levels in both age-and sexadjusted and multivariable adjusted models (P=0.02 for 1 SD increment in SDF-1; Table 4 ). The association of SDF-1 with †P value for the association of ln(SDF-1) as a continuous variable with clinical outcomes. ‡Model 2: adjusted for age, sex, systolic blood pressure, hypertension treatment, total cholesterol, HDL, diabetes mellitus, smoking status, statin use. After excluding HDL from model 2, the HR (95% CI) per 1 SD increment in ln(SDF-1) did not change for CVD, and the P value was insignificant (P=0.11). For MI, exclusion of HDL from model 2 had a HR=1.2 (1.0-1.5) and P=0.020. §Model 2: adjusted for age, sex, systolic blood pressure, hypertension treatment, HDL, body mass index, diabetes mellitus, smoking status, atrial fibrillation, coronary heart disease, and valvular heart disease. ‖Model 3: adjusted for age, sex, systolic blood pressure, hypertension treatment, total cholesterol, HDL, diabetes mellitus, smoking status, angina, atherosclerotic CVD, and HF. CD34+ cells remained statistically significant after adjustment for clinical covariates (P=0.02).
Discussion
On the basis of GWAS results linking the CXCL12-CXCR4 axis to CAD 2-4 and LTL, 5 we explored the relationships of plasma SDF-1, the protein coded by CXCL12, to CVD outcomes and CVD risk factors. In addition, we examined LTL and CD34+ cell frequency as intermediate phenotypes. 9 Our findings are 3-fold. First, SDF-1 levels were associated with several CVD risk factors. Second, higher SDF-1 levels were associated with HF (continuous model adjusted for clinical HF risk factors, P=0.04) and all-cause mortality (continuous model adjusted for risk factors, P=0.003) but not with atherosclerotic CVD. Finally, SDF-1 levels were associated with CD34+ cell frequency (continuous model adjusted for CVD risk factors, P=0.02) but not with LTL.
Extensive phenotypic data from the Framingham Heart Study allowed us to investigate the relationships of SDF-1 to several CVD risk factors in a large sample size of 3359 individuals. In multivariable adjusted models, we found that SDF-1 levels were associated with age, smoking status, and HDL-cholesterol ( Table I in the online-only Data Supplement) . Previous studies have reported similar associations between plasma SDF-1 and clinical CVD risk factors. 14, 15 To explore the association of SDF-1 with CVD further, we analyzed the association of SDF-1 with MI and found that SDF-1 was associated with MI when HDL-cholesterol was not included as a covariate in the multivariable model (P=0.02); however, that association was attenuated when HDLcholesterol was included as a covariate ( Table II in the onlineonly Data Supplement). Thus, we conclude that the (inverse) association of SDF-1 with HDL-cholesterol is partly responsible for the attenuation of the association of SDF-1 with MI. Analyses of cause-specific mortality revealed that SDF-1 levels were associated to deaths caused by CVD (P=0.02) and deaths from other or unknown causes (P=0.003) but not with cancer deaths (Table II in the online-only Data Supplement).
Single nucleotide polymorphisms rs501120 and rs1746048 at the CXCL12 locus that were previously reported to be associated with MI/CAD 2,4,16 were found to be associated with increased SDF-1 levels in our Framingham participants (P≤0.0005 in age-and sex-adjusted models; Table III in the online-only Data Supplement). These findings are consistent with the PennCath Study that found a similar effect size and directionality between rs1746048 and CAD/MI, 17 and the Bruneck Study that found an association between rs1746048 and carotid intimal-medial thickness. 18 Although the literature and our preliminary data suggest that the rs1746048-C allele is associated with higher SDF-1 levels, inferences linking the SDF-1 risk allele to atherogenesis should be made with caution.
We found that SDF-1 levels were associated with risk of HF and death. Higher SDF-1 levels were associated with a 20% increase in risk of new-onset HF (HR per 1 SD increment in ln(SDF-1), 1.2; 95% CI, 1.0-1.5; P=0.04) after adjusting for HF clinical risk factors; this association was attenuated after adjusting for plasma BNP levels. We also found an association of SDF-1 levels with all-cause mortality (HR per one SD increment, 1.2; 95% CI, 1.1-1.3; P=0.003 after adjusting for clinical covariates). The association between SDF-1 and allcause mortality in the general population is novel. 
Figure.
Ten-year survival according to quartile of plasma stromal cell-derived factor 1 α (SDF-1). Kaplan-Meier survival plots are unadjusted for covariates. A log-rank test of survival across quartiles of SDF-1 is highly significant (P<0.001).
A recent prospective study by Mehta et al 15 reported an association of SDF-1 with incident MI, and death in a kidney disease cohort. Our results for MI and HF complement their findings. Of note, as was the case in our analyses, Mehta et al 15 found an association between SDF-1 and MI in a model that did not adjust for HDL. In addition, an investigation from the Diabetes Heart Study found an association of rs1746048 at the CXCL12 locus with all-cause mortality in people with type 2 diabetes mellitus. 19 We found that plasma SDF-1 was associated with reduced frequency of CD34+ cell phenotypes, an association that persisted after adjusting for CVD risk factors. This inverse relationship contrasts with mouse models that suggest a direct association between SDF-1 and CD34+, a circulating cell marker associated with progenitor cell activity. Previous studies have found that SDF-1 binds to the CXCR4 receptor found on CD34+ cells and directs CD34+ cell release from the bone marrow. 20 The release of CD34+ cells aids in neovascularization and angiogenesis, processes that may mediate tissue healing in the context of CVD. 13 Our findings are consistent with population-based studies that have shown that CD34+ frequency is inversely related to CVD risk factors (age and smoking status) and a higher Framingham Risk Score. 21 Several lines of evidence implicate an association of SDF-1 with HDL-cholesterol, and we therefore hypothesize that HDL-cholesterol modulates the CXCL12-CXCR4 axis. HDL-cholesterol was significantly (P<0.0001) associated with SDF-1 levels in our multivariable model. In addition, HDL-cholesterol was the major covariate that attenuated the association of SDF-1 with MI. Of note, a GWAS of HDL-cholesterol identified a suggestive signal for rs768676 (P=4.3×10 −6 ) located near CXCL12. 22 Although these merging lines of evidence are highly speculative, the relationship of SDF-1 to HDL-cholesterol warrants further exploration.
Our study has several limitations. We measured SDF-1 levels at one time point. Evidence suggests that there is acute modulation of SDF-1 levels in humans. 23 The number of incident atherosclerotic CVD and HF events in our analyses was modest, thereby limiting our power. Our study was restricted to a predominantly white, middle-aged sample, thus our ability to generalize our findings to other groups is limited. Finally, the association of SDF-1 with mortality and HF warrants replication in other studies. Model 1: adjusted for age and sex; model 2: adjusted for age, sex, body mass index, total cholesterol/high-density lipoproteincholesterol ratio, smoking status, diabetes mellitus, systolic blood pressure, hypertension treatment. SDF-1 indicates stromal cellderived factor 1 α.
*Values reflect least square means (SE). †P value for the association of ln(SDF-1) as a continuous variable with CD34+. ‡1 SD of ln(SDF-1): 0.26.
